Deutsche Bank reiterates buy on Chiron (CHIR).
Analyst Dennis Harp says the higher guidance beat his Street-high $0.37 estimate and $0.32 consensus. Harp believes strong earnings per share resulted from firm sales of Chiron's influenza vaccine, which peak in the third quarter, and blood tests for detecting HIV and hepatitis C. He notes a recent trend in the drug for cystic fibrosis is positive.
Harp expects the company to report strength in other product lines. He says he will adjust estimates upward upon the company's release of details of third quarter results on Oct. 23.